in the absence of a submission from the holder of the marketing authorisation:
omalizumab (Xolair®) is not recommended for use within NHSScotland.
Indication under review: As add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps for whom therapy with INC does not provide adequate disease control.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice619KB (PDF)
Medicine details
- Medicine name:
- omalizumab (Xolair)
- SMC ID:
- SMC2344
- Indication:
As add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps for whom therapy with INC does not provide adequate disease control.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 February 2021